Merck KGaA agrees to acquire Silence Therapeutics for $20 per ADS

• Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, with an enterprise value of $1.1 billion.
• Shareholders will receive $20 cash per American Depositary Share, representing three ordinary shares, or $6.6667 per ordinary share.
• The offer represents a 130% premium to the October 16, 2026, closing price and 82% above the $10.99 30-day volume-weighted average.
• Completion is expected in the first quarter of 2027, subject to shareholder and court approval, regulatory clearances and customary closing conditions.
• The acquisition will expand Merck's specialty and rare-disease pipeline, adding Divesiran, a polycythemia vera treatment candidate being advanced toward Phase 3 development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019615040) on October 19, 2026, and is solely responsible for the information contained therein.